Drug Trial Radar · NCT03486990
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Last checked: Nov 19, 2026Latest source record: Jun 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jan 23, 2018
Primary completion
May 24, 2019
Study completion Jul 22, 2019
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- COUR Pharmaceutical Development Company, Inc.
- First posted
- Apr 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease. The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and urine, and study subject health will also be monitored by vital signs such as blood pressure, electrocardiogram (ECG), and physical examination.
Conditions
- Celiac Disease
Interventions
TIMP-GLIADrug
intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Day 180
- Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse EventsTime frame: From Day 1 up to Day 180
- Number of Participants With Clinically Significant Physical Examination FindingsTime frame: From Day 1 up to Day 60
- Number of Participants With Clinically Significant Electrocardiograms (ECG) FindingsTime frame: From Day 1 up to Day 60
- Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation LevelsTime frame: From Day 1 up to Day 60
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs ValuesTime frame: From Day 1 up to Day 60
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3Time frame: Baseline (Day 1 pre-dose) and Day 3
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7Time frame: Baseline (Day 1 pre-dose) and Day 7
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8Time frame: Baseline (Day 1 pre-dose) and Day 8
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10Time frame: Baseline (Day 1 pre-dose) and Day 10
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14Time frame: Baseline (Day 1 pre-dose) and Day 14
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38Time frame: Baseline (Day 1 pre-dose) and Day 38
- Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60Time frame: Baseline (Day 1 pre-dose) and Day 60
- Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1Time frame: Baseline (Day 1 pre-dose) and 15 minutes (min) post-dose on Day 1
- Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1Time frame: Baseline (Day 1 pre-dose) and 30 min post-dose on Day 1
- Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2Time frame: Baseline (Day 1 pre-dose) and Day 2
- Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and UrinalysisTime frame: From Day 1 up to Day 60
- Part A (Greater Than or Equal to [>=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release MarkersTime frame: Part A (>=4.0 mg/kg): Day 1 pre-dose up to 144 hours post-dose on Day 7; Part B: Day 8 pre-dose up to 144 hours post-dose on Day 14
- Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: From Day 1 up to Day 60
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Jacksonville Center For Clinical Research
Jacksonville, Florida
Mass General Hospital Translational and Clinical Research Centers
Boston, Massachusetts
Mayo Gastroenterology Research Unit
Rochester, Minnesota
Prism Clinical Research
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.